Genetics of dilated cardiomyopathy

Annals of Medicine

Volumn 39, Issue 2, 2007, Pages 91-107

  Kärkkäinen, Satu ^a   Peuhkurinen, Keijo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cardiomyopathy; Dilated; Gene

Indexed keywords

ACTIN; ALPHA ACTININ; CONNECTIN; DESMIN; DYSTROPHIN; LAMIN A; LAMIN C; LIM PROTEIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN BETA; PHOSPHOLAMBAN; POTASSIUM CHANNEL; SARCOGLYCAN; THYMOPOIETIN; TROPOMYOSIN; TROPONIN C; TROPONIN I; TROPONIN T;

CALCIUM METABOLISM; CHROMOSOMAL LOCALIZATION; CONGESTIVE CARDIOMYOPATHY; GENE DELETION; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SCREENING; HEART CONTRACTION; HEART FAILURE; HEREDITY; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SARCOMERE;

CARDIOMYOPATHY, DILATED; CYTOSKELETAL PROTEINS; GENETIC SCREENING; HUMANS; MUSCLE PROTEINS; MUTATION; NUCLEAR PROTEINS; SARCOMERES;

EID: 34247124771     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890601145821     Document Type: Review

References (162)

1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93:841-2.
2. Abelmann WH. Doxorubicin cardiomyopathy. Hosp Pract. 1982;17:17-8.
3. Valantine HA, Hunt SA, Fowler MB, Billingham ME, Schroeder JS. Frequency of familial nature of dilated cardiomyopathy and usefulness of cardiac transplantation in this subset. Am J Cardiol. 1989;63:959-63.
4. Codd MB, Sugrue DD, Gersh BJ, Melton LJ 3rd. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation. 1989;80:564-72.
5. Williams D, Olsen EG. Prevalence of overt dilated cardiomyopathy in two regions of England. Br Heart J. 1985;54:153-55.
6. Bagger J, Baandrup U, Rasmussen K, Moller M, Vesterlund T. Cardiomyopathy in western Denmark. Br Heart J. 1984;52:327-31.
7. Gillum R. Idiopathic dilated cardiomyopathy. Epidemiolgy. 1994;5:383-5.
8. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564-75.
9. Towbin J, Lowe A, Colan S, Sleeper L, Orav E, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867-76.
10. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela A, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol. 1997;146:385-93.
11. Gregori D, Rocco C, Miocic S, Mestroni L. Estimating th efrequency of familial dilated cardiomyopathy in the presence of misclassification errors. J Appl Stat. 2001;28:53-62.
12. Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 1998;31:186-94.
13. Keeling PJ, Gang Y, Smith G, Seo H, Bent SE, Murday V, et al. Familial dilated cardiomyopathy in the United Kingdom. Br Heart J. 1995;73:417-21.
14. Baig MK, Goldman JH, Caforio AL, Coonar AS, Keeling PJ, McKenna WJ. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol. 1998;31:195-201.
15. Mestroni L, Rocco C, Gregori D, Sinagra G, Di Lenarda A, Miocic S, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol. 1999;34:181-90.
16. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77-82.
17. Evans W. Familial cardiomegaly. Br Heart J. 1949;11:68-82.
18. Muntoni F, Cau M, Ganau A, Congiu R, Arvedi G, Mateddu A, et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med. 1993;329:921-5.
19. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 1993;87:1854-65.
20. Arbustini E, Pilotto A, Repetto A, Grasso M, Negri A, Diegoli M, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/Cdefect-related disease. J Am Coll Cardiol. 2002;39:981-90.
21. Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet. 1996;12:385-9.
22. Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation. 2000;101:473-6.
23. Daehmlow S, Erdmann J, Knueppel T, Gille C, Froemmel C, Hummel M, et al. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem Biophys Res Commun. 2002;298:116.
24. D'Adamo P, Fassone L, Gedeon A, Janssen EA, Bione S, Bolhuis PA, et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet. 1997;61:862-7.
25. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341:1715-24.
26. Genschel J, Schmidt HH. Mutations in the LMNA gene encoding lamin A/C. Hum Mutat. 2000;16:451-9.
27. Gerull B, Gramlich M, Atherton J, McNabb M, Trombitas K, Sasse-Klaassen S, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet. 2002;14:14.
28. Hanson EL, Jakobs PM, Keegan H, Coates K, Bousman S, Dienel NH, et al. Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy. J Card Fail. 2002;8:28-32.
29. Jakobs PM, Hanson EL, Crispell KA, Toy W, Keegan H, Schilling K, et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. J Card Fail. 2001;7:249-56.
30. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, et al. Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy. N Engl J Med. 2000;343:1688-96.
31. Karkkainen S, Miettinen R, Tuomainen P, Karkkainen P, Helio T, Reissell E, et al. A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy. J Mol Med. 2003;81:795-800.
32. Kärkkäinen S, Heliö T, Miettinen R, Tuomainen P, Peltola P, Rummukainen J, et al. A novel mutation, Ser143Pro, in the lamin A/C gene is common in finnish patients with familial dilated cardiomyopathy. Eur Heart J. 2004;25:885-93.
33. Knöll R, Hoshijima M, Hoffman H, Person V, Lorenzen-Schmidt I, Bang M. The cardiac mechanical stretch sensor machinery involves a z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002;111:943-55.
34. Li D, Tapscoft T, Gonzalez O, Burch PE, Quinones MA, Zoghbi WA, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation. 1999;100:461-4.
35. Li D, Czernuszewicz GZ, Gonzalez O, Tapscott T, Karibe A, Durand JB, et al. Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation. 2001;104:2188-93.
36. Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science. 1998;280:750-2.
37. Olson TM, Kishimoto NY, Whitby FG, Michels VV. Mutations that Alter the Surface Charge of Alpha-tropomyosin are Associated with Dilated Cardiomyopathy. J Mol Cell Cardiol. 2001;33:723-32.
38. Olson TM, Illenberger S, Kishimoto NY, Huttelmaier S, Keating MT, Jockusch BM. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation. 2002;105:431-7.
39. Ortiz-Lopez R, Li H, Su J, Goytia V, Towbin JA. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation. 1997;95:2434-40.
40. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410-3.
41. Mohapatra B, Jimenez S, Lin JH, Bowles KR, Coveler KJ, Marx JG, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab. 2003;80:207-15.
42. Murphy RT, Mogensen J, Shaw A, Kubo T, Hughes S, McKenna WJ. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet. 2004;363:371-2.
43. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol. 2003;41:771-80.
44. Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P, Kruse TA, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest. 1999;103:R39-43.
45. McNair W, Ku T, Taylor M, Fain P, Dao D, Wolfel E, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 2004;110:2163-7.
46. Mogensen J, Murphy R, Shaw T, Bahl A, Redwood C, Watkins H, et al. Severe disease expressing of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2004;44:2033-40.
47. Taylor M, Slavov D, Gajewski A, Vlcek S, Ku L, Fain P, et al. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat. 2005;26:566-74.
48. Vatta M, Mohapatra B, Jimenez S, Sanchez X, Faulkner G, Perles Z, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol. 2003;42:2014-17.
49. Bienengraeber M, Olson TM, Selivanov VA, Kathmann EC, O'Cochlain F, Gao F, et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic K(ATP) channel gating. Nat Genet. 2004;36:382-7.
50. Hershberger RE, Hanson EL, Jakobs PM, Keegan H, Coates K, Bousman S, et al. A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation. Am Heart J. 2002;144:1081-6.
51. MacLeod HM, Culley MR, Huber JM, McNally EM. Lamin A/C truncation in dilated cardiomyopathy with conduction disease. BMC Med Genet. 2003;4:4.
52. Verga L, Concardi M, Pilotto A, Bellini O, Pasotti M, Repetto A, et al. Loss of lamin A/C expression revealed by immuno-electron microscopy in dilated cardiomyopathy with atrioventricular block caused by LMNA gene defects. Virchows Arch. 2003;443:664-71.
53. Sinagra G, Di Lenarda A, Brodsky GL, Taylor MR, Muntoni F, Pinamonti B, et al. Current perspective new insights into the molecular basis of familial dilated cardiomyopathy. Ital Heart J. 2001;2:280-6.
54. Karkkainen S, Reissell E, Helio T, Kaartinen M, Tuomainen P, Toivonen L, et al. Novel mutations in the lamin A/C gene in heart transplant recipients with end stage dilated cardiomyopathy. Heart. 2006;92:524-526.
55. Muntoni F, Wilson L, Marrosu G, Marrosu MG, Cianchetti C, Mestroni L, et al. A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest. 1995;96:693-9.
56. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L, et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest. 2000;106:655-62.
57. Komajda M, Charron P, Tesson F. Genetic aspects of heart failure. Eur J Heart Fail. 1999;1:121-6.
58. Mayosi BM, Khogali S, Zhang B, Watkins H. Cardiac and skeletal actin gene mutations are not a common cause of dilated cardiomyopathy. J Med Genet. 1999;36:796-7.
59. Takai E, Akita H, Shiga N, Kanazawa K, Yamada S, Terashima M, et al. Mutational analysis of the cardiac actin gene in familial and sporadic dilated cardiomyopathy. Am J Med Genet. 1999;86:325-7.
60. Tesson F, Sylvius N, Pilotto A, Dubosq-Bidot L, Peuchmaurd M, Bouchier C, et al. Epidemiology of desmin and cardiac actin gene mutations in a european population of dilated cardiomyopathy. Eur Heart J. 2000;21:1872-6.
61. Blair E, Redwood C, de Jesus Oliveira M, Moolman-Smook JC, Brink P, Corfield VA, et al. Mutations of the light meromyosin domain of the beta-myosin heavy chain rod in hypertrophic cardiomyopathy. Circ Res. 2002;90:263-9.
62. Kärkkäinen S, Heliö T, Jääskeläinen P, Miettinen R, Tuomainen P, Ylitalo K, et al. Two novel mutations in the beta-myosin heavy chain gene associated with dilated cardiomyopathy. Eur J Heart Fail. 2004;6:861-8.
63. Villard E, Duboscq-Bidot L, Charron P, Benaiche A, Conraads V, Sylvius N, et al. Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. Eur Heart J. 2005;26:794-803.
64. Robinson P, Mirza M, Knott A, Abdulrazzak H, Willott R, Marston S, et al. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2002;277:40710-6.
65. Stefanelli C, Rosenthal A, Borisov A, Ensing G, Russell M. Novel troponin T mutation in familial dilated cardiomyopathy with gender-dependant severity. Mol Genet Metab. 2004;83:188-96.
66. Fatkin D, Graham RM. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev. 2002;82:945-80.
67. Hein S, Kostin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in heart failure. Cardiovasc Res. 2000;45:273-8.
68. Itoh-Satoh M, Hayashi T, Nishi H, Koga Y, Arimura T, Koyanagi T, et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun. 2002;291:385-93.
69. Maruyama K. Connectin/titin, giant elastic protein of muscle. FASEB J. 1997;11:341-5.
70. Labeit S, Kolmerer B. Titins: giant proteins in charge of muscle ultrastructure and elasticity. Science. 1995;270:293-6.
71. Gerull B, Atherton J, Geupel A, Sasse-Klaassen S, Heuser A, Frenneaux M, et al. Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. J Mol Med. 2006;84:478-83.
72. Valle G, Faulkner G, De Antoni A, Pacchioni B, Pallavicini A, Pandolfo D, et al. Telethonin, a novel sarcomeric protein of heart and skeletal muscle. FEBS Lett. 1997;415:163-8.
73. Hayashi T, Arimura T, Itoh-Satoh M, Ueda K, Hohda S, Inagaki N, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol. 2004;44:2192-201.
74. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science. 1998;279:514-9.
75. Miyamoto Y, Akita H, Shiga N, Takai E, Iwai C, Mizutani K, et al. Frequency and clinical characteristics of dilated cardiomyopathy caused by desmin gene mutation in a Japanese population. Eur Heart J. 2001;22:2284-9.
76. Schonberger J, Seidman CE. Many roads lead to a broken heart: the genetics of dilated cardiomyopathy. Am J Hum Genet. 2001;69:249-60.
77. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med. 2000;342:770-80.
78. Goldfarb LG, Park KY, Cervenakova L, Gorokhova S, Lee HS, Vasconcelos O, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet. 1998;19:402-3.
79. Sjoberg G, Saavedra-Matiz CA, Rosen DR, Wijsman EM, Borg K, Horowitz SH, et al. A missense mutation in the desmin rod domain is associated with autosomal dominant distal myopathy, and exerts a dominant negative effect on filament formation. Hum Mol Genet. 1999;8:2191-8.
80. Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol. 1997;12:329-43.
81. Badorff C, Berkely N, Mehrotra S, Talhouk JW, Rhoads RE, Knowlton KU. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J Biol Chem. 2000;275:11191-7.
82. Hart KA, Hodgson S, Walker A, Cole CG, Johnson L, Dubowitz V, et al. DNA deletions in mild and severe Becker muscular dystrophy. Hum Genet. 1987;75:281-5.
83. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509-17.
84. Berko BA, Swift M. X-linked dilated cardiomyopathy. N Engl J Med. 1987;316:1186-91.
85. Arbustini E, Diegoli M, Morbini P, Dal Bello B, Banchieri N, Pilotto A, et al. Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy. J Am Coll Cardiol. 2000;35:1760-8.
86. Milasin J, Muntoni F, Severini GM, Bartoloni L, Vatta M, Krajinovic M, et al. A point mutation in the 59 splice site of the dystrophin gene first intron responsible for Xlinked dilated cardiomyopathy. Hum Mol Genet. 1996;5:73-9.
87. Feng J, Yan J, Buzin C, Towbin J, Sommer S. Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy. Mol Genet Metab. 2002;77:119.
88. Feng J, Yan JY, Buzin CH, Sommer SS, Towbin JA. Comprehensive mutation scanning of the dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:1120-4.
89. Bies RD, Maeda M, Roberds SL, Holder E, Bohlmeyer T, Young JB, et al. A 5′ dystrophin duplication mutation causes membrane deficiency of alpha-dystroglycan in a family with X-linked cardiomyopathy. J Mol Cell Cardiol. 1997;29:3175-88.
90. Franz WM, Muller M, Muller OJ, Herrmann R, Rothmann T, Cremer M, et al. Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy. Lancet. 2000;355:1781-5.
91. Muntoni F, Di Lenarda A, Porcu M, Sinagra G, Mateddu A, Marrosu G, et al. Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy. Heart. 1997;78:608-12.
92. Kostin S, Scholz D, Shimada T, Maeno Y, Mollnau H, Hein S, et al. The internal and external protein scaffold of the T-tubular system in cardiomyocytes. Cell Tissue Res. 1998;294:449-60.
93. Belkin AM, Ornatsky OI, Glukhova MA, Koteliansky VE. Immunolocalization of meta-vinculin in human smooth and cardiac muscles. J Cell Biol. 1988;107:545-53.
94. Simpson DG, Terracio L, Terracio M, Price RL, Turner DC, Borg TK. Modulation of cardiac myocyte phenotype in vitro by the composition and orientation of the extracellular matrix. J Cell Physiol. 1994;161:89-105.
95. Maeda M, Holder E, Lowes B, Valent S, Bies RD. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation. 1997;95:17-20.
96. Vasile V, Will M, Ommen S, Edwards W, Olson T, Ackerman M. Identification of a metavinculin missense mutation, R975W, associated with both hypertrophic and dilated cardiomyopathy. Mol Genet Metab. 2005;87:169-74.
97. Delta-sarcoglycan (SGCD), Leiden muscular dystrophy pages. Available from: http://www.dmd.nl/sgcd_home.html
98. Nigro V, de Sa Moreira E, Piluso G, Vainzof M, Belsito A, Politano L, et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the deltasarcoglycan gene. Nat Genet. 1996;14:195-8.
99. Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, Politano L, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet. 1997;6:601-7.
100. Kong Y, Flick MJ, Kudla AJ, Konieczny SF. Muscle LIM protein promotes myogenesis by enhancing the activity of MyoD. Mol Cell Biol. 1997;17:4750-60.
101. Yoshida K, Nakamura A, Yazaki M, Ikeda S, Takeda S. Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy. Hum Mol Genet. 1998;7:1129-32.
102. Zhou Q, Ruiz-Lozano P, Martone ME, Chen J. Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J Cell Biol. 2001;155:605-12.
103. Arimura T, Hayashi T, Terada H, Lee S-Y, Zhou Q, Takahashi M, et al. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase. J Biol Chem. 2004;279:6746-52.
104. Goldman RD, Gruenbaum Y, Moir RD, Shumaker DK, Spann TP. Nuclear lamins: building blocks of nuclear architecture. Genes Dev. 2002;16:533-47.
105. Franz WM, Muller OJ, Katus HA. Cardiomyopathies: from genetics to the prospect of treatment. Lancet. 2001;358:1627-37.
106. Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure, assembly, and interactions. J Struct Biol. 1998;122:42-66.
107. Mounkes LC, Burke B, Stewart CL. The A-type lamins: nuclear structural proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends Cardiovasc Med. 2001;11:280-5.
108. Hutchison CJ, Alvarez-Reyes M, Vaughan OA. Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes? J Cell Sci. 2001;114:9-19.
109. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 1999;21:285-8.
110. Emery AE. Emery-Dreifuss syndrome. J Med Genet. 1989;26:637-41.
111. van der Kooi AJ, van Meegen M, Ledderhof TM, McNally EM, de Visser M, Bolhuis PA. Genetic localization of a newly recognized autosomal dominant limb-girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. Am J Hum Genet. 1997;60:891-5.
112. Chaouch M, Allal Y, De Sandre-Giovannoli A, Vallat JM, Amer-el-Khedoud A, Kassouri N, et al. The phenotypic manifestations of autosomal recessive axonal Charcot-Marie-Tooth due to a mutation in Lamin A/C gene. Neuromuscul Disord. 2003;13:60-7.
113. Cao H, Hegele RA. LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J Hum Genet. 2003;48:271-4.
114. Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D'Apice MR, Massart C, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet. 2002;71:426-31.
115. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, Jogia D, et al. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest. 2004;113:357-69.
116. van Berlo JH, deVoogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou RB, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79-83.
117. Meune C, Van Berlo J, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209-10.
118. Foisner R, Gerace L. Integral membrane proteins of the nuclear envelope interact with lamins and chromosomes, and binding is modulated by mitotic phosphorylation. Cell. 1993;73:1267-79.
119. Dechat T, Gotzmann J, Stockinger A, Harris C, Talle M, Siekierka J, et al. Detergent-salt resistance of LAP2alpha in interphase nuclei and phosphorylation-dependent association with chromosomes early in nuclear assembly implies functions in nuclear structure dynamics. EMBO J. 1998;17:4887-902.
120. Vlcek S, Korbei B, Foisner R. Distinct functions of the unique C terminus of LAP2alpha in cell proliferation and nuclear assembly. J Biol Chem. 2002;277:18898-907.
121. Bezzina C, Veldkamp MW, van den Berg MP, Postma AV, Rook MB, Viersma J-W, et al. A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999;85:1206-13.
122. Johns DR. The other human genome: mitochondrial DNA and disease. Nat Med. 1996;2:1065-8.
123. Majamaa-Voltti K, Peuhkurinen K, Kortelainen ML, Hassinen IE, Majamaa K. Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A>G. BMC Cardiovasc Disord. 2002;2:12.
124. Mestroni L, Giacca M. Molecular genetics of dilated cardiomyopathy. Curr Opin Cardiol. 1997;12:303-9.
125. Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, Pierpont ME, Fricker FJ, Lipshultz SE, et al. Specific mitochondrial DNA deletions in idiopathic dilated cardiomyopathy. Cardiovasc Res. 1996;31:306-13.
126. Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, et al. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation. 1995;91:955-61.
127. Schowengerdt KO Jr, Towbin JA. Genetic basis of inherited cardiomyopathies. Curr Opin Cardiol. 1995;10:312-21.
128. Suomalainen A, Paetau A, Leinonen H, Majander A, Peltonen L, Somer H. Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA. Lancet. 1992;340:1319-20.
129. Dimauro S, Davidzon G. Mitochondrial DNA and disease. Ann Med. 2005;37:222-32.
130. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol. 1992;69:1458-66.
131. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med. 1992;117:117-23.
132. Hofmann T, Meinertz T, Kasper W, Geibel A, ZehenderM, Hohnloser S, et al. Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. Am Heart J. 1988;116:1455-63.
133. Schoeller R, Andresen D, Buttner P, Oezcelik K, Vey G, Schroder R. First- or second-degree atrioventricular block as a risk factor in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;71:720-6.
134. Baldasseroni S, De Biase L, Fresco C, Marchionni N, Marini M, Masotti G, et al. Cumulative effect of complete left bundle-branch block and chronic atrial fibrillation on 1-year mortality and hospitalization in patients with congestive heart failure. A report from the Italian network on congestive heart failure (in-CHF database). Eur Heart J. 2002;23:1692-8.
135. Goedel-Meinen L, Hofmann M, Ryba S, Schömig A. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with nonischemic dilated cardiomyopathy. Am J Cardiol. 2001;87:809-12.
136. Mancini M, Eisen H, Kussmaul W, Mull R, Edmunds L, Wilson J. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-86.
137. Junker A, Thayssen P, Nielsen B, Andersen PE. The hemodynamic and prognostic significance of echo-Doppler-proven mitral regurgitation in patients with dilated cardiomyopathy. Cardiology. 1993;83:14-20.
138. Stelken A, Younis L, Jennison T, Miller D, Miller L, Shaw L. Prognostiv value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol. 1996;27:345-52.
139. Blondheim DS, Jacobs LE, Kotler MN, Costacurta GA, Parry WR. Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am Heart J. 1991;122:763-71.
140. Hung J, Koelling T, Semigran MJ, Dec GW, Levine RA, Di Salvo TG. Usefulness of echocardiographic determined tricuspid regurgitation in predicting event-free survival in severe heart failure secondary to idiopathic-dilated cardiomyopathy or to ischemic cardiomyopathy. Am J Cardiol. 1998;82:1301-3, A10.
141. Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J. 2002;144:524-9.
142. Gavazzi A, De Maria R, Parolini M, Porcu M. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol. 2000;85:1114-8.
143. Fauchier L, Babuty D, Poret P, Casset-Senon D, Autret ML, Cosnay P, et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J. 2000;21:306-14.
144. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol. 1990;65:903-8.
145. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75:913-8.
146. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension. 2001;38:1227-32.
147. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838-42.
148. Mestroni L, Maisch B, McKenna WJ, Schwartz K, Charron P, Rocco C, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 1999;20:93-102.
149. Vatta M, Stetson S, Jimenez S, Entman M, Noon G, Bowles N, et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol. 2004;43:811-17.
150. Andersson B, Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 1996;28:162-7.
151. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534-9.
152. McNamara D, Holubkov R, Postava L, Janosko K, MacGowan G, Mathier M, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2019-26.
153. O'Toole L, Stewart M, Padfield P, Channer K. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol. 1998;32:988-94.
154. Sebillon P, Bouchier C, Bidot L, Bonne G, Ahamed K, Charron P. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet. 2003;40:560-7.
155. Durand JB, Bachinski LL, Bieling LC, Czernuszewicz GZ, Abchee AB, Yu QT, et al. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation. 1995;92:3387-9.
156. Jung M, Poepping I, Perrot A, Ellmer AE, Wienker TF, Dietz R, et al. Investigation of a Family with Autosomal Dominant Dilated Cardiomyopathy Defines a Novel Locus on Chromosome 2q14-q22. Am J Hum Genet. 1999;65:1068-77.
157. Siu BL, Niimura H, Osborne JA, Fatkin D, MacRae C, Solomon S, et al. Familial dilated cardiomyopathy locus maps to chromosome 2q31. Circulation. 1999;99:1022-6.
158. Olson TM, Keating MT. Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest. 1996;97:528-32.
159. Sylvius N, Tesson F, Gayet C, Charron P, Benaiche A, Peuchmaurd M, et al. A New Locus for Autosomal Dominant Dilated Cardiomyopathy Identified on Chromosome 6q12-q16. Am J Hum Genet. 2001;68:241-6.
160. Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet. 1997;61:909-17.
161. Krajinovic M, Pinamonti B, Sinagra G, Vatta M, Severini GM, Milasin J, et al. Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group. Am J Hum Genet. 1995;57:846-52.
162. Bowles KR, Gajarski R, Porter P, Goytia V, Bachinski L, Roberts R, et al. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. J Clin Invest. 1996;98:1355-60.